Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.48 USD | +0.47% | -5.15% | +0.47% |
Financials (USD)
Sales 2024 * | 38.84M | Sales 2025 * | 51.19M | Capitalization | 459M |
---|---|---|---|---|---|
Net income 2024 * | -98M | Net income 2025 * | -106M | EV / Sales 2024 * | 3.68 x |
Net cash position 2024 * | 316M | Net cash position 2025 * | 373M | EV / Sales 2025 * | 1.68 x |
P/E ratio 2024 * |
-4.72
x | P/E ratio 2025 * |
-4.83
x | Employees | 162 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.09% |
Latest transcript on Voyager Therapeutics, Inc.
1 day | +0.47% | ||
1 week | -5.15% | ||
Current month | +8.44% | ||
1 month | +0.59% | ||
3 months | +18.60% | ||
6 months | +35.03% | ||
Current year | +0.47% |
Managers | Title | Age | Since |
---|---|---|---|
Alfred Sandrock
CEO | Chief Executive Officer | 67 | 22-02-28 |
Robin Swartz
DFI | Director of Finance/CFO | 53 | 21-08-31 |
Michael Higgins
CHM | Chairman | 61 | 15-07-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
George Scangos
BRD | Director/Board Member | 76 | 23-05-08 |
James Geraghty
BRD | Director/Board Member | 69 | 13-12-31 |
Glenn F. Pierce
BRD | Director/Board Member | 68 | 17-01-04 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 2 M€ | -.--% | ||
0.01% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +3.39% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 8.48 | +0.47% | 390,700 |
24-05-10 | 8.44 | 0.00% | 389,176 |
24-05-09 | 8.44 | -1.52% | 331,423 |
24-05-08 | 8.57 | -2.28% | 389,248 |
24-05-07 | 8.77 | -1.90% | 385,715 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.47% | 459M | |
+26.37% | 44.96B | |
-1.01% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.34% | 26.08B | |
-21.69% | 19.03B | |
+6.23% | 12.75B | |
+26.99% | 12.06B | |
-3.38% | 11.75B |
- Stock Market
- Equities
- VYGR Stock